{"id":"NCT00560755","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety Study of ProQuad® rHA in Infants (V221-037)","officialTitle":"An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured With Recombinant Human Albumin (rHA) When Administered to Children in Their Second Year of Life","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10-24","primaryCompletion":"2008-11-24","completion":"2008-11-24","firstPosted":"2007-11-20","resultsPosted":"2017-10-17","lastUpdate":"2017-10-17"},"enrollment":3388,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Measles","Mumps","Rubella","Varicella"],"interventions":[{"type":"BIOLOGICAL","name":"ProQuad®","otherNames":[]}],"arms":[{"label":"ProQuad®","type":"EXPERIMENTAL"}],"summary":"Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured with recombinant human albumin (rHA) when administered to children in their second year of life.\n\nSecondary objectives: To describe the safety profile of a first dose of ProQuad® manufactured with rHA when administered to children in their second year of life.","primaryOutcome":{"measure":"Percentage of Participants Experiencing an Adverse Event (AE) After ProQuad® Dose 2","timeFrame":"Up to Day 70 (up to 28 days after ProQuad® Dose 2)","effectByArm":[{"arm":"ProQuad®","deltaMin":57.66,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":19},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22772170"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":3342},"commonTop":["Injection site erythema","Pyrexia","Injection site pain","Injection site swelling","Cough"]}}